Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Adults with cystic fibrosis experience higher pain prevalence and severity compared to healthy controls, with significant unmet needs in pain management. New study highlights critical gaps in care.

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients with at least one F508del mutation or another ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...

What is a cystic hygroma? A cystic hygroma — or lymphangioma — is a birth defect that appears as a sac-like structure with a thin wall that most commonly occurs in the head and neck area of an infant.